Product
Daratumumab + Bortezomib + Dexamethasone + Dapagliflozin
1 clinical trial
1 indication
Indication
M-protein Related Cardiac DiseaseClinical trial
A Cross-sectional Study on the Efficacy and Safety of the Combination of Daratumumab+Bortezomib+Dexamethasone Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac DiseaseStatus: Not yet recruiting, Estimated PCD: 2025-01-30